Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2844-2850

  Jackisch, Christian ^a,b   Hahm, Hillary A ^a   Tombal, Bertrand ^a,c   McCloskey, Diane ^a,d   Butash, Kimberly ^a   Davidson, Nancy E ^a   Denmeade, Samuel R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM; DNA FRAGMENT; THAPSIGARGIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CANCER CELL CULTURE; CANCER GROWTH; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOPLASMIC RETICULUM;

APOPTOSIS; BREAST NEOPLASMS; CALCIUM; CELL DIVISION; CELL SURVIVAL; FEMALE; HUMANS; KINETICS; THAPSIGARGIN; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033912370     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. 2+-ATPase. Proc. Natl. Acad. Sci., USA, 87: 2466-2470, 1990.
3. Furuya, Y., Lundmo, P., Short, A., Gill, D., and Isaacs, J. T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 54: 6167-6175, 1994.
4. 1 in individual cells undergoing apoptosis. Cell Calcium, 1: 19-28, 1999.
5. Tombal, B., Weeraratna, A. T., Denmeade, S. R., and Isaacs, J. T. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate, in press, 2000.
6. Qi, X. M., He, F., Zhong, H., and Distelhorst, C. W. Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells. Oncogene, 15: 1207-1212, 1997.
7. McColl, K. S., He, H., Zhong, H., Whitacrre, C. M., Berger, N. A., and Distelhorst, C. W. Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bcl-2 regulated caspase activation. Mol. Cell. Endocrinol., 139: 229-238, 1998.
8. Takadera, T., and Ohyashiki, T. Apoptotic cell death and CPP32-like activation induced by thapsigargin and their prevention by nerve growth factor in PC12 cells. Biochim. Biophys. Acta, 1401: 63-71, 1998.
9. Lin, X. S., Denmeade, S. R., Cisek, L., and Isaacs, J. T. The role of growth arrest in programmed (apoptotic) death of prostate cancer cells by thapsigargin. Prostate, 33: 201-207, 1997.
10. Christensen, S. B., Andersen, A., Kromann, H., Treiman, M., Tombal, B., Denmeade, S. R., and Isaacs, J. T. Thapsigargin analogues for targeting programmed death of androgen-independent prostatic cancer cells. Bioorg. Med. Chem., 7: 1273-1280, 1999.
11. Diamandis, E. P., Yu, H., and Sutherland, D. J. A. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res. Treat., 32: 301-310, 1994.
12. Yu, H., Diamandis, E. P., Levesque, M., Giai, M., Roagna, R., Ponzone, R., Simondi, P., Monne, M., and Croce, C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res. Treat., 40: 171-178, 1996.
13. Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Purification of a human prostate specific antigen. Investig. Urol., 17: 159-163, 1979.
14. Zarghami, N., Grass, L., and Diamandis, E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br. J. Cancer, 75: 579-588, 1997.
15. Yu, H., Giai, M., Diamandis, E., Katsaros, D., Sutherland, D. J. A., Levesque, M. A., Roagna, R., Ponzone, R., and Sismondi, P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res., 55: 2104-2110, 1995.
16. Yu, H., Levesque, M. A., Clark, G. M., and Diamandis, E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res., 4: 1489-1497, 1998.
17. Diamandis, E. P., and Yu, H. Nonprostatic sources of prostate-specific antigen. Urol. Clin. North Am., 24: 275-282, 1997.
18. Lai, L. C., Erbas, H., Lennard, T. W. J., and Peaston, R. T. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int. J. Cancer, 66: 743-746, 1996.
19. Furuya, Y., and Isaacs, J. T. Proliferation dependent versus independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate, 25: 301-309, 1994.
20. Armstrong, D. K., Isaacs, J. T., Ottaviano, Y. L., and Davidson, N. E. Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res., 52: 3418-3424, 1992.
21. 2+ indicator with greatly improved fluorescence properties. J. Biol. Chem., 260: 3440-3450, 1985.
22. Kerr, J. F. R., Wyllie, A. G., and Currie, A. R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer, 26: 239-257, 1972.
23. 2+ concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migration. Clin. Exp. Metastasis, 16: 21-29, 1998.
24. Denmeade, S. R., Lou, W., Malm, J., Lovgren, J., Lilja, H., and Isaacs, J. T. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen. Cancer Res., 57: 4924-4930, 1997.
25. Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A., and Isaacs, J. T. Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res., 58: 2537-2540, 1998.
26. Xing, R., Addington, A. K., and Mason, R. W. Quantification of cathepsins B and L in cells. Biochem. J., 332: 499-505, 1998.
27. Foekens, J. A., Look, M. P., Bolt-de Vries, J., Meijer-van Gelder, M. E., van Putten, W. L. J., and Kiljn, J. G. M. Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br. J. Cancer, 79: 300-307, 1999.
28. Dickson, R. B., Shi, Y. E., and Johnson, M. D. Matrix-degrading proteases in hormone-dependent breast cancer. Breast Cancer Res. Treat., 31: 167-173, 1994.
29. Lin C-Y, Wang, J. K., Torri, J., Dou, L., Sang, Q. A., and Dickson, R. B. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem., 272: 9147-9152, 1997.
30. Anisowicz, A., Sotiropoulou, G., Stenman, G., Mok, S. C., and Sager, R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med., 2: 624-636, 1996.